Options to purchase securities

July 15, 2026 Ref: NEPHROPLUS/SE/59 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Intimation of allotment of Equity Shares pursuant to the Exercise of Stock Options under the NephroPlus Employees Stock Option Scheme, 2011 ("ESOP Scheme 2011") Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Nomination and Remuneration Committee ("NRC" or the "Committee") of the Company, by way of a circular resolution passed on July 14, 2026, has approved the allotment of 2,18,297 (Two Lakh Eighteen Thousand Two Hundred Ninety Seven only) equity shares of face value of ₹2/- each, fully paid-up, pursuant to the exercise of stock options by the eligible employees under the ESOP Scheme 2011. These equity shares shall rank pari-passu with the existing equity shares of the Company in all respects. Consequent to the aforesaid allotment, the issued, subscribed and paid-up equity share capital of the Company has increased from ₹20,06,81,434, comprising 10,03,40,717 equity shares of face value of ₹2/- each, to ₹20,11,18,028, comprising 10,05,59,014 equity shares of face value of ₹2/- each. The Company has obtained the in-principal approvals for listing of the aforesaid equity shares from the National Stock Exchange of India Limited vide letter no. NSE/LIST/54518 dated May 11, 2026, and from BSE Limited vide letter no. DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026. The disclosures required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure A. Further, the details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure B. The aforesaid information is also being made available on the Company’s website at www.nephroplus.com. For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Encl: a/a Annexure A Sr. Particulars Remark 1 Company name and address of Registered Nephrocare Health Services Limited (Formerly Office Nephrocare Health Services Private Limited) 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Shaikpet, Hyderabad, 500081 2 Name of the recognized Stock Exchanges on BSE Limited (BSE) which the company’s shares are listed National Stock Exchange of India Limited (NSE) 3 Filing date of the statement referred in April 10, 2026 regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange 4 Filing Number, if any Reference of In – Principal Approval a. NSE- NSE/LIST/54518 dated May 11, 2026 b. BSE- DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026 5 Title of the Scheme pursuant to which shares NephroPlus Employees Stock Option Scheme, are issued, if any 2011 ("ESOP Scheme 2011") 6 Kind of security to be listed Equity Shares 7 Par value of the shares ₹ 2/- each 8 Date of issue of shares July 14, 2026 9 Number of shares issued 2,18,297 fully paid-up equity shares of Rs. 2/- each 10 Share Certificate No., if applicable Not Applicable 11 Distinctive number of the share, if applicable 10,03,40,718 to 10,05,59,014 (both inclusive) 12 ISIN Number of the shares if issued in Demat INE428V01029 13 Exercise price per share Refer Annexure C 14 Premium per share Refer Annexure C 15 Total Issued shares after this issue 10,05,59,014 16 Total Issued share capital after this issue ₹ 20,11,18,028 17 Details of any lock-in on the shares Not Applicable 18 Date of expiry of lock-in Not Applicable Whether shares identical in all respects to The equity shares allotted shall rank pari-passu 19 existing shares if not, when will they become and are identical in all respects with the existing identical? equity shares including payment of dividend and other rights. 20 Details of listing fees, if payable Not Applicable Annexure B Sr. Particulars Details 1. Brief details of options The present instance pertains to the allotment of 2,18,297 granted equity shares of Rs. 2/- each, pursuant to the exercise of options under the NephroPlus Employees Stock Option Scheme, 2011 ("ESOP Scheme 2011"). 2. Whether the scheme is in Yes terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. 3. Total number of shares The present instance pertains to the allotment of 2,18,297 covered by these options equity shares of Rs. 2/- each, pursuant to the exercise of options under ESOP Scheme 2011". 4. Pricing formula The Exercise Price payable by an Employee upon exercise of the Options shall be as specified in the respective Grant Letter(s) issued under the ESOP Scheme, 2011 and shall be payable in accordance with the terms and conditions thereof. For details please refer Annexure C 5. Options vested Not Applicable. 6. Time within which option may be exercised 7. Options exercised 2,18,297 options were exercised for the current allotment. 8. Money realized by exercise of ₹2,08,18,944.35 (Rupees Two Crore Eight Lakh Eighteen options Thousand Nine Hundred Forty-Four and Thirty-Five Paise only) excluding applicable taxes. 9. Total number of shares arising Each stock option granted under the ESOP Scheme 2011 as a result of exercise of originally entitled the option holder, upon exercise, to options subscribe to one (1) equity share of the Company having a face value of ₹10/- each. Subsequently, pursuant to the sub-division of every equity share of face value ₹10/- each into five (5) equity shares of face value ₹2/- each, approved by the shareholders of the Company on May 26, 2025, and the subsequent bonus issue in the ratio of 1:2 (i.e., two bonus shares for every one equity share held), approved by the Board of Directors and the shareholders on the same date, the outstanding stock options were appropriately adjusted in accordance with the provisions of the ESOP Scheme 2011 and Regulation 5 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, so as to preserve the value of the options and ensure that the employees were neither advantaged nor disadvantaged on account of such corporate actions. Consequently, each original stock option became exercisable into fifteen (15) equity shares of face value ₹2/- each, with the exercise price being correspondingly adjusted in accordance with the adjustment formula prescribed under the ESOP Scheme and the applicable provisions of the SBEB Regulations. Accordingly, the proposed allotment of 2,18,297 equity shares of face value ₹2/- each represents the equity shares to be issued pursuant to the valid exercise of the corresponding adjusted stock options under the ESOP Scheme. 10. Options lapsed Not Applicable. 11. Variation of terms of options Not Applicable. 12. Brief details of significant Options are granted, vested and exercised in accordance terms with the provisions of ESOP Scheme 2011 and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The ESOP Scheme 2011 is administered by the Nomination and Remuneration Committee of the Board of Directors of the Company. The Options granted under the ESOP Scheme 2011 vest over such period and are subject to such time-based, performance-based, business, strategic, market-based and/or other conditions as may be determined by the Nomination and Remuneration Committee at the time of grant and specified in the respective Grant Letter. Vested Options may be exercised within the exercise period specified in the respective Grant Letter. The equity shares allotted pursuant to the exercise of vested Options rank pari passu with the existing equity [Showing first 8,000 characters — download PDF for full document]